Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2019 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2018 Net Income-$27.41M-$27.41MN/M vs Q1 2018 EPS Diluted-$0.04-$0.04N/M vs Q1 2018 Operating Income-$33,792,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$37,107,000N/M ended Mar 31, 2019 · filed May 6, 2019 · 36 d after period end